cobas® eplex system

IVD For in vitro diagnostic use.
cobas eplex system

Fast, reliable syndromic testing for informed therapeutic decisions

The cobas® eplex system simplifies and accelerates multiplex molecular diagnostics, from order entry to result reporting. It features true sample-to-answer workflow, bi-directional laboratory information system (LIS) integration, random and continuous access, and a scalable, modular design, to efficiently adapt to peak demand. With less than 1 minute hands-on time and remote service capabilities, the system reduces downtime while streamlining lab operations. By detecting multiple pathogens from a single patient sample in one rapid test, the cobas® eplex system minimizes the need for multiple tests, saving both time and resources.

Enhanced efficiency with our comprehensive panels

With high sensitivity and specificity, all of our panels support infection control and enable rapid and effective treatment decisions, supporting clinicians in improving patient outcomes.1-4

The cobas® eplex blood culture identification panels (BCID) aid in detecting bacterial and fungal organisms and antibiotic resistance genes directly from positive blood cultures in about 1.5 hours.2-4 They offer the broadest coverage of organisms and resistance markers that cause bloodstream infections (BSIs), including anaerobes, multidrug-resistant organisms (MDROs), and emerging fungal pathogens.2-6 Their broad coverage means that about 95% of currently identified bloodstream infections can be detected early.*2-4 By enabling fast, targeted therapy, the BCID panels support sepsis management, infection control, and antimicrobial stewardship.

Comprehensive coverage of respiratory pathogens beyond influenza, such as respiratory syncytial virus (RSV) and SARS-CoV-2, is critical in patients at higher risk for complications or more severe infections. The cobas® eplex respiratory pathogen panel 2 (RP2)† detects the most common viruses and bacteria causing upper respiratory illness from a single sample in about 1.5 hours.1 This supports effective infection control and respiratory illness management, particularly during high-demand seasons.

To continue addressing the growing demands of diagnostic laboratories, additional panels are in development to expand testing capabilities.**

Two lab technicians viewing a test result on the cobas eplex system
Order to Report
Benefits at a glance

Benefits at a glance

Hand in heart icon, illustrating the patient centered design of the cobas explex system

While many systems offer sample-to-answer solutions, only the cobas® eplex system's unique software ensures seamless integration from order to report, potentially maximizing the benefits of rapid, multiplex molecular diagnostics.7-9

The cobas® eplex system offers many unique solutions that were thoughtfully engineered to address the biggest challenges facing you in the clinical laboratory and to support hospital systems in delivering patient-centered, value-based care.

Positive test result icon, illustrating correct results obtained using the cobas eplex system

Preventable medical errors are now the third leading cause of death in the United States at more than 250,000 per year.10 Automating information transfer has been shown to be effective in reducing many common errors, including patient identity checking and order transcription.11

The cobas® eplex system is uniquely designed with patient safety features in mind so that labs and physicians can have the confidence that they have the right patient, with the right test, and the right result, every time.

  • Reduce the chance of pre-analytical errors with < less than 1 minute hands-on time and guided workflows1-4,7
  • Transcription errors can be eliminated in both order entry and result reporting with bi-directional LIS
Increase, graph icon illustrating the improved efficiency with cobas eplex system

Monitoring and reporting quality control (QC) testing is both a requirement and a best practice to ensure the accuracy of patient results and compliance with lab standards. With on-board QC tracking capabilities and safeguards, you can run controls when required and easily track and report compliance.

In addition to automated QC tracking, the cobas® eplex system provides the following compliance and data management tools:7

  • Integrated data analytics to easily monitor lab performance
  • On-demand epidemiology reports for export and simplified analysis
  • Fully configurable, auto-release of test results

All of these unique capabilities of the cobas® eplex system allow you to reduce the time spent on routine administrative tasks and focus your limited resources on high-value activities that impact patient care and the bottom line.

Related information

A modular and scalable system

cobas eplex system NP
cobas® eplex system NP
  • 3 test bays
  • Throughput (24 hours): 36 patient samples per day
  • Physical dimensions (H x D x W): 23.5" x 19.0" x 21.3", 
    59cm x 48cm x 54cm
cobas eplex system 1 Tower
cobas® eplex system 1 tower
  • 6 test bays
  • Throughput (24 hours): 72 patient samples per day
  • Physical dimensions (H x D x W): 23.5" x 19.0" x 21.3",
    59cm x 48cm x 54cm
cobas eplex system 2 Tower
cobas® eplex system 2 tower
  • 12 test bays
  • Throughput (24 hours): 144 patient samples per day
  • Physical dimensions (H x D x W): 23.5" x 19.0" x 28.5",
    59cm x 48cm x 72cm
cobas eplex 3 tower
cobas® eplex system 3 tower
  • 18 test bays
  • Throughput (24 hours): 216 patient samples per day
  • Physical dimensions (H x D x W): 23.5" x 19.0" x 35.8",
    59cm x 48cm x 91cm
cobas eplex system 4 Tower
cobas® eplex system 4 tower
  • 24 test bays
  • Throughput (24 hours): 288 patient samples per day
  • Physical dimensions (H x D x W): 23.5" x 19.0" x 43.0",
    59cm x 48cm x 109cm

Use left and right arrow keys to scroll between the tabs

Overview

Ordering information

Technical specifications

View full table
close

Technical specifications

Parameter Value
Weight 1-tower system 49kg (108 lbs)
Dimensions 1-tower system 59 cm x 48 cm x 54 cm (24.0” x 19.0” x 21.0”)
LIS compatibility

ASTM LIS 1-A & LIS 2-A2 (Bi-directional); HL7 v2.3 (Bi-directional); Flat file (.csv, .xml and .txt)
Supported barcodes

Aztec, Codabar, Code 39, Code 93, Code 128, Data Matrix, EAN, Interleaved 2 of 5, JAN, MaxiCode, UPC
Power requirements

100-240 Vac, 50/60 Hz
Environmental conditions

Ambient temperature: 15 – 30°C; relative humidity: 15 – 85% (non-condensing)
Noise generation

≤ 60dBA
Back     Next

Technical documents

multilangimg
   
Document repository
error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Related products

...
    ...

    Contact us

    Do you have any questions about our products or services? We’re here to help. Fill out the form to have a Roche representative contact you.

    *Based on ePlex Panel inclusivity compared to 2 representative US clinical data sets (not intended as sensitivity/performance claims): i) The GenMark prospective clinical study database (n=1,978); ii) 12 months of BCID clinical isolate data from 5 geographically diverse US hospitals (n=15,793).

    **An updated version of the respiratory pathogen panel and a meningitis & encephalitis panel are currently in development and are not available for sale in the United States.

    †This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency use Authorization (EUA) for use by authorized laboratories. This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2 and multiple respiratory viral and bacterial organisms and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


    References:

    1. GenMark Diagnostics, Inc. cobas® eplex respiratory pathogen panel 2 Method Sheet (v2.0). 2025.

    2. GenMark Diagnostics, Inc. cobas® eplex blood culture identification gram-positive (BCID-GP) panel Method Sheet (v1.0). 2024.

    3. GenMark Diagnostics, Inc. cobas® eplex blood culture identification gram-negative (BCID-GN) panel Method Sheet (v1.0). 2024.

    4. GenMark Diagnostics, Inc. cobas® eplex blood culture identification fungal panel (BCID-FP) Package insert. (vC). 2024.

    5. bioMerieux. BioFire Blood Culture Identification 2 (BCID2) Panel package insert. FIT-PRT-0841-02 June 2020.

    6. Nanosphere Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) package insert. 27- 00030-01, Rev. B; October 2012.

    7. GenMark Diagnostics, Inc. cobas® eplex® System Instrument Software 3.0 User Assistance (v1.0) 2024.

    8. bioMerieux. BIOFIRE FilmArray Torch Operators Manual, HTFA-PRT-0001-09, 2023.

    9. Qiagen, QIAstat-Dx Analyzer 1.0 User Manual, HB-2942-001, 2021.

    10. Makary MA and Michael D. Medical error—the third leading cause of death in the US. BMJ. 2016;353:i2139.

    11. The National Academics of Sciences, Engineering, and Medicine. [Internet; cited 2025 Nov 3]. Available from: https://www.nap.edu/read/9728/chapter/4#39.